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Background. Recent studies have shown that cerebral vascularity may be impaired in Alzheimer’s disease. Cerebral vasomotor
reactivity could be an important biomarker for this pathology. Aims. The aim of this study was to investigate the alterations in
cerebral vascularmotor reactivity inAlzheimer’s disease subjects and to associate these changeswith their cognitive scores.Methods.
We recruited subjects with a diagnosis of Alzheimer’s disease and healthy controls. Demographic, clinical, imaging, and cognitive
test were obtained. Then all participants performed a cerebral vascular motor reactivity test with 7% CO2 and cerebral blood flow
velocities (CBFV) were recorded with transcranial doppler ultrasound before and after the test. Results. We recruited 45 subjects,
26 (21 female) Alzheimer’s disease participants and 19 (15 female) healthy controls. There were no differences in baseline cerebral
blood flow velocities between the groups. After the cerebral vasomotor reactivity test, absolute mean difference in mean CBFV
(ΔCBFV-m) was 8.70±4.14 versus 4.81±6.96 (p<0.01), respectively. Calculated percentage of change (%CVMR) was lower in the
AD group 7.45±18.25 versus 23.29±17.48, and there was a positive but weak correlation with mini-mental scores (𝜌=0.337, p=0.023).
Conclusions. In this study, Alzheimer’s disease subjects showed significant changes in all absolute cerebral blood flow velocities after
the cerebral vasomotor reactivity test with CO2, but only diastolic phase responses were statistically significant.Therewas a positive
but weak correlation between cerebral vasomotor reactivity and cognitive scores. Further studies are needed to investigate these
effects in larger Latin-American samples.
1. Introduction
Alzheimer’s disease (AD) is the leading cause of dementia
in both industrialized and developing countries, accounting
for most of all dementia cases [1, 2]. Furthermore, AD affects
an estimate of 46.8 million people worldwide, approximately
5.2% of the world population, and it is calculated that this
number will double by the year 2030 [3]. Therefore, it is
important to develop cost-effective treatment and preven-
tion strategies. However, the pathophysiological processes
behind neurodegeneration in AD remain unclear. Neither
an effective treatment or a prevention strategy have been
developed.
It is well known that amyloid-𝛽 protein deposits are
the classical pathological finding in subjects affected with
AD. These protein deposits are spread across the central
nervous system including the brain vessel walls, leading
to impaired endothelial function and blood-brain barrier
disruption among other pathological phenomena [4]. On
the other hand, epidemiological studies have demonstrated
that cardiovascular disease (CVD) represents a risk factor
for AD development and progression. Common CVD risk
factors as hypertension, diabetes mellitus, and dyslipidemia
are associated with increased AD frequency [5]. Particularly,
participants with peripheral arterial disease (PAD) have a
relative risk (RR) of 2.5 to develop AD, relative to those
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without PAD [6]. Thus, cardiovascular disease may promote
and contribute to the development of AD, and in a parallel
way, AD could also contribute to vascular damage and cere-
bral hypoperfusion progression through cerebral amyloid
angiopathy and other mechanisms [7].
In normal subjects, the neurovascular unit (NVU), which
is a functional unit consisting of neuronal, glial, and vascular
cells, is responsible for maintaining an adequate cerebral
blood flow (CBF) in response to internal and external stimuli.
The NVU (and CBF in consequence) can respond to changes
in blood CO2 concentration, which is the termed cerebral
vascular motor reactivity or cerebral vasomotor reactivity
(CVMR) [4]. Hence CVMR arises as an important biomarker
of CBF regulation and NVU function, and in consequence of
cerebral vascular health [8]. CVMR attenuation along with
vascular structural alterations had been evidenced in several
preclinical studies with animal models of AD [9] and human
brain specimen studies [10]. Measurement of CBF changes
in humans has been done previously using BOLD-MR,
SPECT, and PET and indirectly with transcranial doppler
ultrasonography (TCD). The latter is a dynamic noninvasive
method that measures cerebral blood flow velocity (CBFV)
in the brain vessels, most frequently in the middle cerebral
artery (MCA).
The aim of this studywas tomeasure and compare CVMR
responsewithTCD inADparticipants versus control subjects
matched for age and sex and to associate these changes with
their cognitive scores in a Latin-American AD sample.
2. Materials and Methods
2.1. Study Population. A case-control study was conducted,
and participants were consecutively recruited from the Neu-
rology Outpatient Clinic of the Universidad Autonoma of
Nuevo Leon, Monterrey, Mexico, from July 2009 to July
2010. Inclusion criteria were subjects with a diagnosis of
AD according to the DSM IV and NINCDS-ADRA Criteria
[11]. Healthy controls (HC) matched for age (±3 years),
sex, and vascular risk factors were also recruited. Subjects
who did not attend the imaging study appointment and
those with severe functional impairment (inability to attend
the appointments), psychiatric disorder (at the time of AD
diagnosis), history of myocardial infarction, angina pectoris,
transient ischemic attack or stroke, severe carotid stenosis
(>50%), and respiratory or cardiac conditions were excluded
from the study. Informed consent was obtained for every
participant in the study (and the family caregivers in AD
participants) and this study was approved by the Local Ethics
Committee.
2.2. Magnetic Resonance Imaging (MRI), Carotid Ultrasound
Study, and Blood Samples. To evaluate for possible con-
founding factors, an MRI study was made to assess for
whitematter damage (leukoaraiosis) and a carotid ultrasound
study to assess for carotid plaques and an intima-media
thickness (IMT). In addition, blood samples were obtained
for every participant and processed for common vascular
risk biomarkers: cholesterol, low-density lipoprotein, high-
density lipoprotein, triglycerides, C-reactive protein, and
homocysteine.
2.3. Clinical Data, Cognitive and Depression Test. Demo-
graphic and vascular risk factors data were obtained through
a structured clinical interview, and participants were clas-
sified as having diabetes mellitus (DM) if they were using
antidiabetic drugs or with self-reported history; also hyper-
tension and dyslipidemia status were assessed similarly.
Cognitive function was evaluated with Mini-Mental State
Examination test (MMSE) Spanish version [12, 13] and the
Geriatric Depression Scale in its 15-item Spanish version was
applied to screen for depression symptoms [14].
2.4. Cerebral Vasomotor Reactivity Protocol and TCD Study.
CBFVs and Pulsatility Indices (PIs) were evaluated with a
2 MHz Probe TCD (Rimed; Smart-Lite SL-1 TCD System)
with the participant in a supine position; measurements were
taken in the left MCA by the same examiner at an insonation
deep of 55 millimeters through the temporal window. After
baseline CBFVs and PIs measurement, a CVMR test was
made asking the patient to inhale a 7% CO2-air mixture
for 5 minutes according to Deplanque et al. [15]. After the
CO2 inhalation, CBFV and PIs measurement were repeated.
Variables collected were CBFV, systolic CBFV (CBFV-S),
diastolic (CBFV-D), andmean (CBFV-M). PIs weremanually
calculated using the formula ofGosling andKing [16], CVMR
was calculated as CBFV post CO2 - CBFV at baseline/CBFV
at baseline x 100, and calculations were made for all veloc-
ities. Mean arterial pressure (MAP) was obtained prior to
and after the CVMR test. All tests were conducted in the
vascular research laboratory of the Neurology Department at
a constant temperature and with a 10-minute resting period
before initial CBFV evaluation.
2.5. Statistical Analyses. Comparisons of continuous vari-
ables were analyzed with a Mann–Whitney U test and a chi-
square test was used for categorical variables. A multivariate
analysis was made to adjust for age and sex. Finally, a
Spearman correlation test between MMSE results, CBFVs
difference, and %CVMRs was performed. Results were con-
sidered significant if p=<0.05. All statistical analysis was
made using SPSS v22.0.
3. Results
3.1. Participant General Characteristics. A total of 51 sub-
jects, 26 participants with AD and 25 healthy, were initially
included; however, 6 controls who did not attend the ini-
tial carotid ultrasound and MRI study appointment were
excluded. General demographic, cognitive, and depression
test results are shown in Table 1. There were no statistically
significant differences in cardiovascular risk factors or GDS
scores between both groups. There was a significant differ-
ence in MMSE scores between AD participants and HC.
3.2. MRI, Carotid Doppler Ultrasound Study, and Vascular
Biomarkers Results. There were no differences in the severity
of white matter damage between the groups. In addition,
there were no significant differences in the presence of carotid
plaques or intima-media thickness estimate. There were no
statistically significant differences between AD participants
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Table 1: Demographic, clinical, imaging, and blood sample characteristics of Alzheimer’s disease and healthy control participants.
Characteristic Alzheimer’s disease (n=26) Healthy controls (n=19)
(a) Demographic and clinical
Age, median (range)∗ 78(67-93) 78 (59-90)
Gender, fem (%) 21 (81%) 15 (79%)
Education years, median (range) 3(0-15) 6 (0-16)
Diabetes mellitus, n (%) 9(35%) 4(21%)
Hypertension, n (%) 13(50%) 8(42%)
Dyslipidemia, n (%) 5(19%) 9(47%)
Active smoking, n (%) 6(23%) 7(37%)
MMSE, media (±SD) 14.08(±5.80) † 27±(3.20)
GDS, median (range) 4 (0-9) 3 (0-7)
(b) MRI study and carotid ultrasound
Leukoaraiosis >5mm 6 (23%) 2 (11%)
Carotid plaques >30% 11 (42%) 6 (32%)
Intima-media thickness 0.902 (0.60 -2.0) 0.826 (0.6-1.10)
(c) Blood samples
Total cholesterol 182.2 ± 36.4 197.6 ± 33.5
LDL 111.6 ± 31.5 129.8 ± 32.3
HDL 36.7 ± 11.5 38.2 ± 9.6
Triglycerides 164.7 ± 100.4 147.5 ± 56.9
CRP 3.7 ± 5.0 6.6 ± 9.1
Homocysteine 10.3 ± 2.9 8.9 ± 3.6
MMSE: Mini-Mental State Examination; BMI: body mass index; GDS: Geriatric Depression Scale 15 item version; MRI: magnetic resonance imaging; LDL:
low-density lipoprotein; HDL: high-density lipoprotein; CRP: C-reactive protein.
∗Years.
†p < 0⋅05.
Table 2: Baseline, post-CO2 test cerebral blood flow velocities, and calculated CVMR.
Healthy Controls
(n=19)
Alzheimer’s disease
(n=26)
Velocities Baselinemean (±SD)
Post-CO2
mean (±SD)
Mean CVMR%
(±SD)
Baseline
mean (±SD)
Post-CO2
mean (±SD)
Mean CVMR %
(±SD)
CBFV-S 69.90 (18.44) 82.64 (14.47) 21.17(17.03) 62.3619.83) 68.30(20.50)† 10.88(15.26)
CBFV-D 26.36 (7.26) 31.86 (7.42) 23.29(17.48) 25.348.21) 27.09(9.78)† 7.45(18.25)††
CBFV-M 49.00 (15.52) 57.70 (14.08) 20.88(14.97) 38.8814.95) 43.69(16.87)† 15.02(27.69)
CBFV-S: cerebral bloodflow velocity-systolic; CBFV-D: cerebral blood flow velocity-diastolic; CBFV-M: cerebral bloodflow velocity-mean; CVMR%: cerebral
vasomotor reactivity as a percentage of change between baseline CBFV and post-CO2 test CBFV.
†p < 0⋅05: comparison of post-CO2 mean CBFV between AD and HC groups.
††p < 0.05: comparison of mean CVMR % between AD and HC groups.
and HC in cholesterol, LDL, HDL, triglycerides, C-reactive
protein, and homocysteine levels. Full results of MRI, carotid
doppler, and blood samples are shown in Table 1.
3.3. Baseline CBFV and PIs Results. Baseline CBFVs in
MCA were obtained from all participants. Table 2 shows
results obtained for both groups. There were no significant
differences in baseline BP (blood pressure), PIs, or any of the
CBFVs between AD participants or HC.
3.4. Cerebral Vasomotor Reactivity Test Results. All recruited
participantswere able to perform the entireCVMR test.There
were significant absolute differences in CBFVs between AD
and HC groups after the CO2 test, and calculated %CVMR
for changes in diastolic, systolic, and mean CBFVs were
statistically significant between both groups; however after
adjusting for age, sex, hypertension, and DM, only changes in
diastolic CVMR remained statistically significant (7.45±18.25
versus 23.29±17.48, p<0.05). Full results are shown in Table 2.
3.5. MMSE Cognitive Test and CBFV. There was a positive
correlation between MMSE results and changes in CBFV-
S (𝜌=0.339, p=0.023), CBFV-D (𝜌=0.422, p=0.004), and
CBFV-M (𝜌=0.299, p=0.046). When correlating MMSE with
%CVMRs, only %CVMR-D (𝜌=0.337, p=0.023) remained
statistically significant.
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4. Discussion
4.1. Main Findings. This study shows that participants with
AD have smaller changes in CBFVs than healthy controls
matched for age, gender, and common vascular risk factors
in response to an inhaled CO2 CVMR test, particularly in
diastolic phase CBFV. Also, this decreased response may not
be related to differences in common vascular risk biomarkers
such as white matter damage, atherosclerotic disease, choles-
terol, C-reactive protein, or homocysteine levels. As far as
we know, these are the first results published from a Latin-
American AD sample.
4.2. Baseline CBFVs. This study showed no baseline alter-
ation in CBFVs or PIs. Similar results have been previously
published; a study by Lee et al. [17] showed no differences
in baseline CBF between AD participants and HC. Although
a study by Vicenzini et al. [18] found that lower baseline
CBFV and higher PI are present in AD participants, a recent
meta-analysis of hemodynamic studies in demented subjects
performed by Sabayan et al. showed a significant but small
reduction in CBFVs and increased PIs in AD [19]. This
cerebral hypoperfusion condition in patients with AD could
be the result of small vessel damage driven by amyloid
angiopathy, a landmark of AD brain findings among other
alterations [20]. Increased PIs may be also explained by
damage to cerebral microvasculature, leading to an increase
in vascular resistance.
4.3. CVMR Alterations. CVMR attenuation in AD has also
been shown in other studies; Abeelen et al. [21] showed
a CVMR alteration in AD participants related to healthy
controls in response to hypercapnia. Studies that used other
imaging modalities such as BOLD-fMRI [22] also reported
similar results. The fact that, in this study, only changes in
diastolic phase CBFVs were statistically significant could be
explained by the low sample size; however, the reason is
unknown and future studies to address this observation are
required. Impairment of CVMR has been proposed to be a
consequence of multiple mechanisms, of which amyloid-𝛽
protein deposits in small cerebral vessels are the most impor-
tant. This accumulation of amyloid-𝛽 leads to a decreased
vasodilator synthesis driven by oxidative stress and disrup-
tion of blood-brain barrier with a subsequent perivascular
edema that further reduces CVMR response, in addition to
other glial and neuronal intrinsic pathological factors such as
cholinergic dysfunction [4]. Pathophysiological mechanism
pathways to vascular damage could be different in Latin-
American population; a studymade byO’Bryant et al. showed
that Mexican American participants with AD could have a
significantly different serum biomarker profile [23]; also the
progression of these mechanisms is faster Latin-American
subjects compared to non-Hispanic whites [24].
Vascular pathology plays a central role in the develop-
ment and progression of Alzheimer’s disease. These changes
may appear before the clinical manifestation [25]; also people
with Apolipoprotein E high risk alleles may have an impaired
baseline vascular function [26]. Although the pathophysio-
logical processes of these alterations in CVMR within the
context of dementia andADare not fully understood, it iswell
known that CVD and traditional vascular risk factors such as
age, dyslipidemia, diabetes mellitus, hypertension, smoking,
and metabolic syndrome can individually lead to alterations
in CVMR, fostering the vascular dysfunction in AD [5]. A
population-based study published by Wolters et al. revealed
that subjects with higher CVMRs were less likely to develop
AD (hazard ratio of 0.84) particularly those carrying APOe4
alleles (hazard ratio of 0.77) at 11.5 years of follow-up; these
results give clinical usefulness to the measurement of CVMR
in healthy individuals at risk [27].
4.4. MMSE and CVMR. This study showed a weak posi-
tive correlation between MMSE results and CBFVs change
before and after CVMR test, although a study by Lee et
al. [17] showed no correlation between MMSE and CVMR.
Clinically, vascular dysfunction in AD results in further
cognitive decline and functional impairment; a study made
by Silvestrini et al. demonstrated a moderate correlation
between both characteristics, showing that a breath holding
index below 1 as a measure of CVMR is correlated with a
progressive decline in MMSE scores [23]. Further studies
are needed to measure the real magnitude of the correlation
between MMSE and CVMR.
4.5. Limitations. This study had several limitations: first, we
did not perform a measurement of end-tidal CO2 because of
limited resources andwe did not assess CVMR in hypocapnia
condition. Also, AD diagnosis was clinical criteria-based,
and severity of dementia was not directly assessed. Only
MCA measurements were taken for feasibility purposes.
DM as a cardiovascular risk factor was considered with
only clinical history without considering blood sugar or
HbA1c readings; thus there was not a distinction between
those with controlled or uncontrolled DM and neither for
hypertension or dyslipidemia. Weight/BMI and PAD were
not assessed. Also, subjects with a GDS-15 score compatible
with probable depression in the study appointment were not
excluded. Moreover, 6 healthy control participants who did
not attend the MRI appointment were excluded; however,
baseline results showed no differences. Despite this, these
results should be confirmed in a larger sample size.
5. Conclusions
Despite being an indirect measurement of overall vascu-
lar function, measurement of baseline CBFVs and CVMR
responses in AD subjects with TCD is easy, safe, and cost-
effective. Therefore, these virtues make this technique ideal
for its use in the clinical setting of developing countries. This
study adds strength to the general reproducibility of these
results for the use of CVMR test in the clinical setting of AD
with Latin-American samples.
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